A Phase 3, Multi-center, Open-label Study To Investigate Safety, Efficacy, And Tolerability Of Sildenafil Citrate In Pediatric Patients With Pulmonary Arterial Hypertension
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 16 May 2017
At a glance
- Drugs Sildenafil (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions; Pharmacodynamics; Registrational; Therapeutic Use
- Sponsors Pfizer
- 07 Jun 2017 Biomarkers information updated
- 15 Feb 2017 Status changed from recruiting to active, no longer recruiting.
- 19 Jul 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Jul 2016.